Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity

BACKGROUND: Rifaximin has demonstrated efficacy and safety for diarrhea-predominant irritable bowel syndrome (IBS-D). AIM: To determine the rifaximin repeat treatment effect on fecal bacterial antibiotic susceptibility. METHODS: Patients with IBS in Trial 3 (TARGET 3) study who responded to open-lab...

Descripción completa

Detalles Bibliográficos
Autores principales: Pimentel, M., Cash, B. D., Lembo, A., Wolf, R. A., Israel, R. J., Schoenfeld, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561162/
https://www.ncbi.nlm.nih.gov/pubmed/28589238
http://dx.doi.org/10.1007/s10620-017-4598-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561162/
https://www.ncbi.nlm.nih.gov/pubmed/28589238
http://dx.doi.org/10.1007/s10620-017-4598-7

Ejemplares similares